Retrospective  	Retrospective  	 JJ	B-NP
study  	study  	 NN	I-NP
of  	of  	 IN	I-NP
clinical  	clinical  	 JJ	I-NP
features  	features  	 NNS	I-NP
of  	of  	 IN	I-NP
neuromyelitis  	neuromyelitis  	 JJ	I-NP
optica  	optica  	 JJ	I-NP
spectrum  	spectrum  	 NN	I-NP
disease  	disease  	 NN	I-NP
with  	with  	 IN	O
connective  	connective  	 JJ	B-NP
tissue  	tissue  	 NN	I-NP
disease  	disease  	 NN	I-NP
To  	To  	 TO	O
explore  	explore  	 VB	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
features  	features  	 NNS	I-NP
of  	of  	 IN	I-NP
neuromyelitis  	neuromyelitis  	 JJ	I-NP
optica  	optica  	 NNS	I-NP
( 	( 	 -LRB-	O
NMO 	NMO 	 NNP	B-NP
)  	)  	 -RRB-	O
spectrum  	spectrum  	 NN	B-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
NMOSD 	NMOSD 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
connective  	connective  	 JJ	B-NP
tissue  	tissue  	 NN	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CTD 	CTD 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
clinical  	clinical  	 JJ	B-NP
features  	features  	 NNS	I-NP
of  	of  	 IN	O
184  	184  	 CD	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD  	NMOSD  	 NNP	I-NP
patients  	patients  	 NNS	I-NP
( 	( 	 -LRB-	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD 	NMOSD 	 NNP	I-NP
:  	:  	 :	O
119 	119 	 CD	O
/ 	/ 	 CD	O
184 	184 	 CD	O
,  	,  	 ,	O
64.7 	64.7 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD 	NMOSD-CTD 	 NNP	I-NP
:  	:  	 :	O
65 	65 	 CD	O
/ 	/ 	 CD	O
184 	184 	 CD	O
,  	,  	 ,	O
35.3 	35.3 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
from  	from  	 IN	O
May  	May  	 NNP	O
2013  	2013  	 CD	O
to  	to  	 TO	O
May  	May  	 NNP	O
2014  	2014  	 CD	O
were  	were  	 VBD	O
analyzed  	analyzed  	 JJ	O
retrospectively 	retrospectively 	 NN	O
.  	.  	 .	O
And  	And  	 CC	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
in  	in  	 IN	O
NMOSD  	NMOSD  	 NNP	B-NP
was  	was  	 VBD	O
evaluated 	evaluated 	 VBN	O
.  	.  	 .	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD  	NMOSD-CTD  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
had  	had  	 VBD	O
significantly  	significantly  	 RB	O
higher  	higher  	 RBR	O
female  	female  	 JJ	O
percentage  	percentage  	 NN	O
( 	( 	 -LRB-	O
93.8 	93.8 	 CD	O
%  	%  	 NN	O
vs  	vs  	 VBD	O
83.2 	83.2 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
P  	P  	 NN	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
significantly  	significantly  	 RB	O
higher  	higher  	 JJR	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
cerebral  	cerebral  	 JJ	B-NP
spinal  	spinal  	 JJ	I-NP
fluid  	fluid  	 NN	I-NP
( 	( 	 -LRB-	O
CSF 	CSF 	 NNP	B-NP
) 	) 	 -RRB-	O
-restricted  	-restricted  	 JJ	O
oligoclonal  	oligoclonal  	 JJ	B-NP
band  	band  	 NN	I-NP
( 	( 	 -LRB-	O
OB 	OB 	 NNP	B-NP
) 	) 	 -RRB-	O
( 	( 	 -LRB-	O
41.5 	41.5 	 CD	O
%  	%  	 NN	O
vs  	vs  	 VBD	O
21.9 	21.9 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
P  	P  	 NN	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
As  	As  	 RB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD  	NMOSD-CTD  	 JJ	I-NP
counterparts 	counterparts 	 NNS	I-NP
,  	,  	 ,	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD  	NMOSD  	 NNP	I-NP
patients  	patients  	 NNS	I-NP
had  	had  	 VBD	O
significantly  	significantly  	 RB	O
higher  	higher  	 JJR	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
non-specific  	non-specific  	 JJ	B-NP
lesions  	lesions  	 NNS	I-NP
on  	on  	 IN	O
brain  	brain  	 NN	B-NP
MRI  	MRI  	 NNP	I-NP
( 	( 	 -LRB-	O
62.5 	62.5 	 CD	O
%  	%  	 NN	O
vs  	vs  	 VBD	O
35.9 	35.9 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
P  	P  	 NN	O
< 	< 	 SYM	O
0.01 	0.01 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
After  	After  	 IN	O
> 	> 	 CD	O
6  	6  	 CD	O
months  	months  	 NNS	O
consecutive  	consecutive  	 JJ	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
drugs 	drugs 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
relapse  	relapse  	 JJ	B-NP
rate  	rate  	 NN	I-NP
post-treatment  	post-treatment  	 NNS	I-NP
( 	( 	 -LRB-	O
0.36  	0.36  	 CD	O
±  	±  	 CD	O
0.85 	0.85 	 CD	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
lower  	lower  	 JJR	O
than  	than  	 IN	O
that  	that  	 DT	O
pre-treatment  	pre-treatment  	 JJ	B-NP
( 	( 	 -LRB-	O
2.91  	2.91  	 CD	O
±  	±  	 CD	O
4.10 	4.10 	 CD	O
,  	,  	 ,	O
P  	P  	 NN	O
< 	< 	 SYM	O
0.01 	0.01 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
And  	And  	 CC	O
no  	no  	 DT	O
significant  	significant  	 JJ	O
difference  	difference  	 NN	O
existed  	existed  	 VBD	O
in  	in  	 IN	O
expanded  	expanded  	 JJ	B-NP
disability  	disability  	 NN	I-NP
status  	status  	 NN	I-NP
scale  	scale  	 NN	I-NP
( 	( 	 -LRB-	O
EDSS 	EDSS 	 NNP	B-NP
)  	)  	 -RRB-	O
score  	score  	 NN	O
between  	between  	 IN	O
pre-and  	pre-and  	 JJ	B-NP
post-treatment 	post-treatment 	 NN	I-NP
.  	.  	 .	O
When  	When  	 WRB	O
using  	using  	 VBG	O
azathioprine  	azathioprine  	 NNS	B-NP
( 	( 	 -LRB-	O
AZA 	AZA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
relapse  	relapse  	 NN	O
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD  	NMOSD-CTD  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
( 	( 	 -LRB-	O
50.0 	50.0 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
versus  	versus  	 FW	O
NMO 	NMO 	 FW	B-NP
/ 	/ 	 FW	I-NP
NMOSD  	NMOSD  	 FW	I-NP
ones  	ones  	 FW	I-NP
( 	( 	 -LRB-	O
18.5 	18.5 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.064 	0.064 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
When  	When  	 WRB	O
using  	using  	 VBG	O
cyclophosphamide  	cyclophosphamide  	 NNS	B-NP
( 	( 	 -LRB-	O
CTX 	CTX 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
there  	there  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
such  	such  	 JJ	O
significant  	significant  	 JJ	O
difference 	difference 	 NN	O
.  	.  	 .	O
Female  	Female  	 JJ	O
patients  	patients  	 NNS	O
are  	are  	 VBP	O
more  	more  	 RBR	O
susceptible  	susceptible  	 JJ	O
to  	to  	 TO	O
have  	have  	 VB	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD  	NMOSD  	 NNP	I-NP
with  	with  	 IN	O
CTD 	CTD 	 NNP	B-NP
.  	.  	 .	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD  	NMOSD-CTD  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
tend  	tend  	 VBP	O
to  	to  	 TO	O
have  	have  	 VB	O
higher  	higher  	 JJR	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
CSF-restricted  	CSF-restricted  	 NNP	B-NP
OB  	OB  	 NNP	I-NP
and  	and  	 CC	O
fewer  	fewer  	 JJR	O
non-specific  	non-specific  	 JJ	B-NP
lesions  	lesions  	 NNS	I-NP
on  	on  	 IN	O
brain  	brain  	 NN	B-NP
MRI 	MRI 	 NNP	I-NP
.  	.  	 .	O
AZA  	AZA  	 NNP	B-NP
and  	and  	 CC	O
CTX  	CTX  	 NNP	B-NP
may  	may  	 MD	O
effectively  	effectively  	 RB	O
reduce  	reduce  	 VB	O
relapses  	relapses  	 VBN	O
in  	in  	 IN	O
both  	both  	 DT	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD  	NMOSD  	 NNP	I-NP
and  	and  	 CC	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD  	NMOSD-CTD  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
However  	However  	 RB	O
CTX  	CTX  	 NNP	B-NP
is  	is  	 VBZ	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
AZA  	AZA  	 NNP	B-NP
for  	for  	 IN	I-NP
reducing  	reducing  	 VBG	I-NP
relapses  	relapses  	 NN	I-NP
in  	in  	 IN	O
NMO 	NMO 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NMOSD-CTD  	NMOSD-CTD  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
